Breaking News

Eisai Enters Joint Development Agreement for COVID-19 Therapeutics

Aims to understand the mechanism of COVID-19 aggravation based on SARS-CoV-2 infection and to create drugs that prevent the aggravation of COVID-19.

By: Contract Pharma

Contract Pharma Staff

Eisai Co. has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, and Yokohama City University) in Japan to develop therapeutics to prevent COVID-19. This joint research project “Development of Therapeutics for Novel Coronavirus Infectious Disease (COVID-19)” was adopted for the second public call by the Japan Agency for Medical Research and Development (AMED) as part of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters